<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824135</url>
  </required_header>
  <id_info>
    <org_study_id>REFLEX</org_study_id>
    <secondary_id>NCI-2011-03677</secondary_id>
    <nct_id>NCT00824135</nct_id>
  </id_info>
  <brief_title>Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies</brief_title>
  <official_title>Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with refractory hematologic malignancies including those who develop recurrent&#xD;
      disease after allogeneic hematopoietic stem cell transplantation (HSCT) have a dismal&#xD;
      prognosis. Historically, both regimen-related mortality and disease recurrence have been&#xD;
      significant causes of treatment failure in this heavily pre-treated patient population. The&#xD;
      investigators institution has utilized mismatched family member donors for these patients for&#xD;
      several reasons: (1) Only 30% of patients have matched related donors available; (2)&#xD;
      transplantation can be performed more rapidly since the time to unrelated donor&#xD;
      trans-plantation averages 3 to 4 months; (3) the alloimmune reactivity of natural killer (NK)&#xD;
      cells following haploidentical HSCT has been shown to reduce relapse rates in certain patient&#xD;
      groups; and, (4) no other curative treatment options are available.&#xD;
&#xD;
      In the present trial, the investigators propose a novel conditioning regimen using&#xD;
      clofarabine in an effort to enhance cytotoxicity while simultaneously reducing regimen&#xD;
      related toxicity. In this phase I trial, the goal is to determine the maximum tolerated dose&#xD;
      (MTD) of clofarabine when used in combination with melphalan and thiotepa pre-transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this trial is to determine the maximum tolerated dose of clofarabine&#xD;
      in combination with thiotepa and melphalan as a conditioning regimen for a haploidentical&#xD;
      stem cell transplant with an engineered graft depleted of CD3+ cells. Study participants will&#xD;
      children and young adults with refractory hematologic malignancies.&#xD;
&#xD;
      Secondary objectives include the following:&#xD;
&#xD;
        -  To describe the one-year overall survival (OS) and event-free survival (EFS) rates in&#xD;
           these study participants.&#xD;
&#xD;
        -  To determine the time to hematopoietic recovery and donor cell engraftment following&#xD;
           this study treatment.&#xD;
&#xD;
        -  To estimate the cumulative incidence of relapse in study participants.&#xD;
&#xD;
        -  To estimate the incidence of overall grade II-IV and grade III-IV acute GVHD and the&#xD;
           rate of chronic GVHD.&#xD;
&#xD;
        -  To estimate the incidence and describe the causes of non-hematologic regimen-related&#xD;
           toxicity and regimen-related mortality in the first 100 days post HSCT.&#xD;
&#xD;
        -  To explore the biologic significance of soluble interleukin-2 (IL-2) receptor, tumor&#xD;
           necrosis factor (TNF), and lymphocyte reconstitution (qualitative and quantitative, V&#xD;
           beta spectratyping, TREC&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the MTD and DLT of clofarabine in combination with thiotepa and melphalan as a conditioning regimen for a haploidentical HSCT with an engineered graft depleted of CD3+ cells obtained by negative selection with OKT3 on the CliniMACS system.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>One dose intravenously every 24 hrs for five days total.&#xD;
Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplantation, Hematopoietic</intervention_name>
    <description>Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OKT3</intervention_name>
    <description>Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total&#xD;
Muromonab-CD3</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Orthoclone OKT3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>5 mg/kg/day intravenous every 12 hours (2 doses total)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>60mg/m2 intravenous every 12 hours for 2 doses total.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil 600 mg/m2 intravenous two times a day&#xD;
(continue for approximately 2 months or as clinically indicated)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 intravenous for 1 dose total</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rituxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age less than or equal to 21 years old; may be greater than 21 years old if a&#xD;
             previously treated St. Jude patient and within 3 years of completion of most recent&#xD;
             prior disease specific therapy.&#xD;
&#xD;
          -  One of the following refractory hematologic malignancies (chemoresistant relapse or&#xD;
             primary induction failure) or diagnoses:&#xD;
&#xD;
          -  ALL&#xD;
&#xD;
          -  AML (&gt;25% blasts in the bone marrow)&#xD;
&#xD;
          -  secondary AML/MDS&#xD;
&#xD;
          -  CML in accelerated phase or blast crisis&#xD;
&#xD;
          -  juvenile myelomonocytic leukemia (JMML)&#xD;
&#xD;
          -  myelodysplastic syndrome (MDS)&#xD;
&#xD;
          -  Hodgkin or non-Hodgkin lymphoma (NHL) with residual or recurrent disease following&#xD;
             autologous HSCT, who are unable to undergo autologous HSCT due to chemo-resistant&#xD;
             disease or inability to have an acceptable quantity of tumor-free stem cells collected&#xD;
             (&gt; 1 x 108 TNC/kg marrow or &gt; 1 x 106 CD34+/kg PBS&#xD;
&#xD;
          -  patients with a hematologic malignancy who have undergone prior allogeneic HSCT or who&#xD;
             have a co-morbid condition that in the medical opinion of medical faculty (Division of&#xD;
             Bone Marrow Transplantation and Cellular Therapy) makes standard myeloablation&#xD;
             prohibitive&#xD;
&#xD;
          -  Does not have any other active malignancy other than the one for which this transplant&#xD;
             is indicated&#xD;
&#xD;
          -  Cardiac shortening fraction greater than or equal to 25%&#xD;
&#xD;
          -  For pediatric patients, creatinine clearance greater than or equal to 90 ml/min/1.73&#xD;
             m2 according to the Schwartz formula for estimated GFR (ml/min/1.73m2) = k*height&#xD;
             (cm)/serum creatinine (mg/dL). k is a proportionality constant that varies with age&#xD;
             and is a function of urinary creatinine clearance per unit of body size; 0.45 up to 12&#xD;
             months of age; 0.55 children and adolescent girls; and 0.70 for adolescent boys&#xD;
&#xD;
          -  For adolescent or adult patients, serum creatinine 1.0 mg/dL; if serum creatinine 1.0&#xD;
             mg/dL, then the estimated glomerular filtration rate (GFR) must be 60 mL/min/1.73 m2&#xD;
             as calculated by the Modification of Diet in Renal Disease equation where predicted&#xD;
             GFR (ml/min/1.73 m2) = 186 x (serum creatinine)-1.154 x (age in years)-0.023 x (0.742&#xD;
             if patient is female) x (1.212 if patient is black)&#xD;
&#xD;
          -  Forced vital capacity (FVC) greater than or equal to 40% of predicted value or pulse&#xD;
             oximetry greater than or equal to 92% on room air.&#xD;
&#xD;
          -  Karnofsky or Lansky (age-dependent) performance score of greater than or equal to 50&#xD;
             (See APPENDIX A)&#xD;
&#xD;
          -  Does not have active acute or active chronic GVHD defined as requiring medical&#xD;
             therapy.&#xD;
&#xD;
          -  Does not have active acute bronchiolitis obliterans (BO) or bronchiolitis obliterans&#xD;
             organizing pneumonia (BOOP).&#xD;
&#xD;
          -  Has a suitable HLA partially matched family member donor available for stem cell&#xD;
             donation&#xD;
&#xD;
          -  Bilirubin less than or equal to 1.5 times the upper limit of normal for age.&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) less than or equal to 1.5 times the upper limit of&#xD;
             normal for age.&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) less than or equal to 1.5 times the upper limit of&#xD;
             normal for age.&#xD;
&#xD;
          -  Not pregnant (confirmed by negative serum or urine pregnancy test within 14 days prior&#xD;
             to enrollment).&#xD;
&#xD;
          -  Not lactating&#xD;
&#xD;
        Inclusion criteria (stem cell donor):&#xD;
&#xD;
          -  Partially HLA-matched family member.&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant (confirmed by negative serum or urine pregnancy test within 14 days prior&#xD;
             to enrollment).&#xD;
&#xD;
          -  Not lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon Triplett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <last_update_submitted>December 30, 2016</last_update_submitted>
  <last_update_submitted_qc>December 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem Cell Transplantation, Hematopoietic</keyword>
  <keyword>Peripheral Blood Stem Cell Transplantation</keyword>
  <keyword>Maximal Tolerated Dose</keyword>
  <keyword>Clofarabine</keyword>
  <keyword>Hematological Malignancies</keyword>
  <keyword>Apheresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Muromonab-CD3</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

